Solventum (NYSE:SOLV) Stock Rating Lowered by UBS Group

Solventum (NYSE:SOLV) was downgraded by analysts at UBS Group from a “buy” rating to a “neutral” rating in a report issued on Thursday, MarketBeat.com reports. They presently have a $50.00 price target on the stock. UBS Group’s price target would indicate a potential downside of 32.66% from the company’s current price.

Other research analysts also recently issued research reports about the stock. Mizuho set a $100.00 price target on shares of Solventum and gave the stock an “outperform” rating in a research report on Tuesday, January 20th. Stifel Nicolaus reduced their price target on shares of Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. Piper Sandler reduced their price target on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. Finally, BTIG Research reiterated a “buy” rating and set a $89.00 price target on shares of Solventum in a research report on Wednesday, May 6th. Eight analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Solventum presently has a consensus rating of “Moderate Buy” and an average price target of $84.25.

Solventum Stock Down 0.2%

SOLV opened at $74.26 on Thursday. The firm’s 50-day simple moving average is $67.94 and its 200-day simple moving average is $74.56. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. Solventum has a twelve month low of $62.38 and a twelve month high of $88.20. The firm has a market cap of $12.86 billion, a price-to-earnings ratio of 9.10, a PEG ratio of 1.15 and a beta of 0.59.

Solventum (NYSE:SOLV) last posted its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same quarter in the prior year, the firm earned $1.34 EPS. The firm’s quarterly revenue was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Equities research analysts anticipate that Solventum will post 6.58 EPS for the current fiscal year.

Insider Transactions at Solventum

In related news, Director Amy Mcbride Wendell purchased 1,475 shares of Solventum stock in a transaction that occurred on Tuesday, March 10th. The shares were acquired at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the transaction, the director directly owned 5,039 shares in the company, valued at approximately $342,803.17. This represents a 41.39% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.24% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Assetmark Inc. boosted its stake in shares of Solventum by 21.4% in the 4th quarter. Assetmark Inc. now owns 725 shares of the company’s stock valued at $57,000 after purchasing an additional 128 shares during the last quarter. Hilltop National Bank boosted its stake in shares of Solventum by 71.3% in the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock valued at $25,000 after purchasing an additional 129 shares during the last quarter. Allworth Financial LP boosted its stake in shares of Solventum by 2.8% in the 3rd quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock valued at $350,000 after purchasing an additional 129 shares during the last quarter. CIBC Private Wealth Group LLC boosted its stake in shares of Solventum by 0.5% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock valued at $1,804,000 after purchasing an additional 134 shares during the last quarter. Finally, BOKF NA boosted its stake in shares of Solventum by 6.9% in the 3rd quarter. BOKF NA now owns 2,193 shares of the company’s stock valued at $160,000 after purchasing an additional 141 shares during the last quarter.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.